Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02616 INTRAVAGINAL PSC-RANTES PROTECTS AGAINST VAGINAL TRANSMISSION OF SHIV-162P TO MACAQUE MONKEYS

Veazey, Ronald (1)
Offord, R (2), Hartley, O (2), Blauvelt, A (3), Dufour, J(1), Piatak Jr., M (4), Lifson, J (4), Mosier, D (5), Lederman M (6)
(1) Tulane National Primate Research Center, Tulane Medical School, Covington, La; (2) University of Geneva, Geneva, Switzerland; (3) Dermatology Branch, Nci, Bethesda, Md; (4) Nci-Frederick, Frederick Md; (5) Scripps Research Institute, La Jolla, Ca; (6) Case Western Reserve University, Cleveland, Oh.

We are currently developing microbicides that may block HIV-1 infection by binding to receptors on susceptible cells and interfere with HIV attachment and/or fusion on mucosal surfaces. Since HIV-1 utilizes one or more chemokine receptors for attachment, we are testing the potential for RANTES analogs to block HIV-1 transmission in rhesus macaques. We have developed an amino-terminus modified RANTES analog called PSC RANTES that is several orders of magnitude more potent than native RANTES for inhibition of HIV replication. To assess its efficacy as a microbicide, Depo-provera treated macaques were intravaginally administered 4 ml of PSC RANTES diluted in saline at concentrations of 1 mM (n=5), 330 uM (n=5), 100 uM (n=5), or 1-10 uM (n=5). Five received saline alone as controls. 15 minutes after dosing, animals were intravaginally exposed to 300 TCID50 of the CCR5-using SHIV162P3. Viral loads in plasma were monitored weekly by RT-PCR. All five macaques treated with the highest dose (1 mM), 4/5 treated with 330 uM dose and 3/5 treated with 100uM dose of PSC RANTES were completely protected against vaginal transmission, as evidenced by undetectable virus in plasma. In contrast, 11/15 macaques in the low-dose groups or control group became infected. These results clearly demonstrate that PSC RANTES provides complete protection against vaginal transmission of a CCR5-utilizing SHIV. Since CCR5- utilizing strains predominate in early mucosal transmission, these findings suggest that this may be an effective strategy for preventing mucosal HIV-1 transmission.

Dr. Ronald S. Veazey
Tulane National Primate Res. Ctr, 18703 Three Rivers Road, Covington, LA. USA ,70433
(Telephone) 985-871-6228 (Fax) 985-871-6510 (E-mail) veazey@tpc.tulane.edu